tradingkey.logo


tradingkey.logo


Bicycle Therapeutics PLC

BCYC
6.940USD
-0.250-3.48%
取匕時間 ET15分遅れの株䟡
346.09M時䟡総額
損倱額盎近12ヶ月PER


Bicycle Therapeutics PLC

6.940
-0.250-3.48%

詳现情報 Bicycle Therapeutics PLC 䌁業名

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.

Bicycle Therapeutics PLCの䌁業情報


䌁業コヌドBCYC
䌚瀟名Bicycle Therapeutics PLC
䞊堎日May 23, 2019
最高経営責任者「CEO」Lee (Kevin)
埓業員数305
蚌刞皮類Depository Receipt
決算期末May 23
本瀟所圚地Blocks A & B, Portway Building
郜垂CAMBRIDGE
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United Kingdom
郵䟿番号CB21 6GS
電話番号11441223261503
りェブサむトhttps://www.bicycletherapeutics.com/
䌁業コヌドBCYC
䞊堎日May 23, 2019
最高経営責任者「CEO」Lee (Kevin)

Bicycle Therapeutics PLCの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-23.43%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+73.03%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-65.69%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+49.49%
Charles Swanton
Charles Swanton
Independent Director
Independent Director
--
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
--
--
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Independent Director
Independent Director
--
--
Mr. Eric Westin, M.D.
Mr. Eric Westin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephen Sands
Mr. Stephen Sands
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-23.43%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+73.03%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-65.69%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+49.49%
Charles Swanton
Charles Swanton
Independent Director
Independent Director
--
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sun, Nov 16
曎新時刻: Sun, Nov 16
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Baker Bros. Advisors LP
21.80%
Forbion Capital Partners
6.91%
Armistice Capital LLC
5.96%
Westfield Capital Management Company, L.P.
5.91%
Invus Public Equities Advisors, LLC
4.03%
他の
55.38%
株䞻統蚈
株䞻統蚈
比率
Baker Bros. Advisors LP
21.80%
Forbion Capital Partners
6.91%
Armistice Capital LLC
5.96%
Westfield Capital Management Company, L.P.
5.91%
Invus Public Equities Advisors, LLC
4.03%
他の
55.38%
皮類
株䞻統蚈
比率
Hedge Fund
37.45%
Investment Advisor
15.62%
Investment Advisor/Hedge Fund
14.44%
Venture Capital
7.08%
Research Firm
3.61%
Individual Investor
1.59%
Pension Fund
0.49%
Family Office
0.25%
他の
19.47%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
242
39.22M
114.58%
+31.05K
2025Q3
266
40.06M
126.53%
-4.18M
2025Q2
264
44.22M
123.05%
-338.39K
2025Q1
249
44.93M
127.83%
-16.05M
2024Q4
249
44.97M
130.44%
+273.71K
2024Q3
245
43.83M
123.27%
+876.01K
2024Q2
237
43.44M
106.75%
+5.72M
2024Q1
253
34.16M
113.53%
-14.25M
2023Q4
258
34.56M
124.36%
-3.64M
2023Q3
255
38.68M
90.77%
+8.35M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Baker Bros. Advisors LP
10.89M
21.83%
--
--
Jun 30, 2025
Forbion Capital Partners
3.45M
6.92%
--
--
Jun 30, 2025
Armistice Capital LLC
2.80M
5.61%
+128.00K
+4.79%
Jun 30, 2025
Westfield Capital Management Company, L.P.
2.78M
5.58%
+123.19K
+4.64%
Jun 30, 2025
Invus Public Equities Advisors, LLC
2.01M
4.04%
+200.00K
+11.03%
Jun 30, 2025
Long Focus Capital Management LLC
1.32M
2.64%
+23.54K
+1.82%
Jun 30, 2025
T. Rowe Price Associates, Inc.
1.47M
2.94%
-68.19K
-4.44%
Jun 30, 2025
Candriam Luxembourg S.A.
1.32M
2.65%
--
--
Aug 31, 2025
Acadian Asset Management LLC
698.50K
1.4%
+572.44K
+454.09%
Jun 30, 2025
Candriam Belgium S.A.
1.17M
2.35%
-32.82K
-2.72%
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
Virtus LifeSci Biotech Clinical Trials ETF
0.63%
Invesco NASDAQ Future Gen 200 ETF
0.59%
Harbor Health Care ETF
0.23%
ALPS Medical Breakthroughs ETF
0.17%
iShares Health Innovation Active ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
SPDR S&P International Small Cap ETF
0.03%
iShares Biotechnology ETF
0.02%
ActivePassive International Equity ETF
0%
詳现を芋る
Virtus LifeSci Biotech Clinical Trials ETF
比率0.63%
Invesco NASDAQ Future Gen 200 ETF
比率0.59%
Harbor Health Care ETF
比率0.23%
ALPS Medical Breakthroughs ETF
比率0.17%
iShares Health Innovation Active ETF
比率0.05%
Invesco Nasdaq Biotechnology ETF
比率0.04%
ProShares Ultra Nasdaq Biotechnology
比率0.04%
SPDR S&P International Small Cap ETF
比率0.03%
iShares Biotechnology ETF
比率0.02%
ActivePassive International Equity ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Bicycle Therapeutics PLCの䞊䜍5名の株䞻は誰ですか


Bicycle Therapeutics PLCの䞊䜍5名の株䞻は以䞋のずおりです。
Baker Bros. Advisors LPは10.89M株を保有しおおり、これは党䜓の21.83%に盞圓したす。
Forbion Capital Partnersは3.45M株を保有しおおり、これは党䜓の6.92%に盞圓したす。
Armistice Capital LLCは2.80M株を保有しおおり、これは党䜓の5.61%に盞圓したす。
Westfield Capital Management Company, L.P.は2.78M株を保有しおおり、これは党䜓の5.58%に盞圓したす。
Invus Public Equities Advisors, LLCは2.01M株を保有しおおり、これは党䜓の4.04%に盞圓したす。

Bicycle Therapeutics PLCの株䞻タむプ䞊䜍3皮は䜕ですか


Bicycle Therapeutics PLCの株䞻タむプ䞊䜍3皮は、
Baker Bros. Advisors LP
Forbion Capital Partners
Armistice Capital LLC

Bicycle Therapeutics PLCBCYCの株匏を保有しおいる機関の数はいく぀ですか


2025Q4時点で、Bicycle Therapeutics PLCの株匏を保有しおいる機関は242瀟あり、保有株匏の総垂堎䟡倀は玄39.22Mで、党䜓の114.58%を占めおいたす。2025Q3ず比范しお、機関の持ち株は-11.95%増加しおいたす。

Bicycle Therapeutics PLCの最倧の収益源は䜕ですか


--においお、--郚門がBicycle Therapeutics PLCにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™